

Reference Data

1st Quarter - Fiscal Year 2011
(April 1, 2011 to June 30, 2011)

Consolidated Earnings

- Consolidated Financial Data P 1
- Consolidated Balance Sheets P 2
- Consolidated P/L Statement P 3
- Consolidated Sales Breakdown by Segment/Category P 4
- Consolidated Operating Income by Segment P 4
- Consolidated Sales -
 - Leading Brands of Self-Medication Operations P 5
- Consolidated Sales -
 - Leading Products of Prescription Pharmaceutical Operations P 6
- Major Subsidiaries : Trend of Sales and Earnings P 6
- Capital Expenditure P 7
- Depreciation and Amortization P 7
- R&D Expenses P 7
- Subsidiaries and Affiliates P 8

New Drug Development / New Products

- Prescription Pharmaceutical operations:
 - New Drug Development P 9
- Launch of New Products P10

Consolidated Financial Data

(Millions of yen)

	March 2011(FY2010)				March 2012(FY2011)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Net sales	64,557	133,046	207,728	268,632	64,265	136,500	274,000
(YOY%)	(+1.6%)	(+2.5%)	(+2.4%)	(+3.9%)	(-0.5%)	(+2.6%)	(+2.0%)
Self-Medication operations	39,920	85,424	131,133	167,195	39,853	87,000	171,300
Prescription Pharmaceutical operations	24,636	47,621	76,594	101,436	24,412	49,500	102,700
Gross profit*	41,483	85,912	134,373	172,237	41,175	87,700	175,900
Selling, general and administrative expenses	29,560	61,277	94,080	128,154	30,324	66,700	136,400
Research and development expenses	4,743	10,012	15,064	23,677	4,996	12,700	26,200
(% Sales)	(7.3%)	(7.5%)	(7.3%)	(8.8%)	(7.8%)	(9.3%)	(9.6%)
Advertising expenses	3,414	7,238	11,945	15,143	3,463	8,200	16,600
Sales promotion expenses	5,126	11,095	17,777	23,997	5,745	12,800	26,700
Personnel expenses	8,395	16,862	25,425	33,632	8,613	17,000	34,200
Operating income	11,923	24,635	40,292	44,082	10,851	21,000	39,500
(YOY%)	(+90.6%)	(+35.4%)	(+37.8%)	(+27.1%)	(-9.0%)	(-14.8%)	(-10.4%)
Ordinary income	12,930	26,833	43,622	54,077	12,558	23,500	45,500
(YOY%)	(+82.8%)	(+42.3%)	(+42.3%)	(+47.5%)	(-2.9%)	(-12.4%)	(-15.9%)
Net income	7,708	16,219	25,946	34,892	8,052	14,000	28,000
(YOY%)	(+115.3%)	(+56.5%)	(+64.5%)	(+79.1%)	(+4.5%)	(-13.7%)	(-19.8%)
Comprehensive income	5,869	14,324	25,932	31,451	8,827	-	-
(YOY%)	-	-	-	(+7.3%)	(+50.4%)	-	-
EPS (yen)	27.41	57.71	92.48	124.90	29.20	50.76	101.52
BPS (yen)	1,822.60	1,852.39	1,881.26	1,901.74	1,917.95	1,936.04	1,975.05
Dividend per share (yen)	-	12.00	-	27.00	-	12.00	-
Payout ratio	-	-	-	21.6%	-	23.6%	-
Capital expenditure	701	1,944	2,990	7,870	771	3,400	11,000
Depreciation and amortization	2,850	5,742	8,696	11,725	2,694	5,400	11,100
Total assets	597,632	609,872	614,961	618,434	619,583	629,000	640,000
Shareholders' equity	522,296	530,715	534,144	535,231	539,696	545,000	556,000
Return on equity (%)**	-	-	-	6.7%	-	-	5.2%
Return on assets (%)**	-	-	-	5.7%	-	-	4.4%
Equity ratio (%)	85.7%	85.3%	85.1%	84.8%	85.4%	84.9%	85.1%
Overseas sales	3,081	6,202	9,242	12,166	3,120	-	-
Overseas sales ratio (% of total sales)	4.8%	4.7%	4.5%	4.5%	4.9%	-	-
Number of employees	5,694	5,664	5,641	5,622	5,712	-	-

E=Estimates

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

Consolidated Balance Sheets

(Millions of yen)

	End of FY2010		End of 1Q 2011		change	
	(March 31, 11)	% total	(Jun. 30, 11)	% total		
(Assets)						
I Current assets:	233,170	37.7%	241,548	39.0%	+8,377	
Cash and deposits	133,422		134,955		+1,532	
Notes and accounts receivable-trade	65,171		65,309		+137	
Marketable securities	-		3,528		+3,528	Transferred from investment securities:+3,496, Evaluation gain: +30
Inventories	23,040		25,615		+2,574	Merchandise and finished goods: -1,969, Work in progress: -417, Raw materials and supplies: +1,022
Deferred tax assets	8,094		6,554		-1,540	
Others	3,441		5,586		+2,145	
II Fixed assets:	385,263	62.3%	378,034	61.0%	-7,228	
(1) Tangible fixed assets:	90,249	(14.6%)	89,209	(14.4%)	-1,040	
Buildings and structures	44,604		44,123		-480	Taisho: -429, Biofermin Pharmaceutical: -54
Machinery and equipment	7,415		6,990		-424	Taisho: -380, Biofermin Pharmaceutical: -47
Land	32,508		32,488		-20	
Others	5,721		5,608		-113	
(2) Intangible fixed assets:	30,386	(4.9%)	29,426	(4.7%)	-960	
Goodwill	13,397		13,215		-181	Portion of amortization from Taisho Pharmaceutical Indonesia: -149
Sales rights	10,067		9,771		-296	Amortization of sales rights in Asia OTC business: -296
Trademarks	3,186		2,932		-253	VICKS trademark amortization: -187
Software	3,363		3,137		-226	Taisho: -225
Others	372		369		-2	
(3) Investments and other assets:	264,626	(42.8%)	259,399	(41.9%)	-5,227	
Investments in securities	198,390		194,146		-4,244	Bond acquisition: +5,000, Bond redemption: -6,000, Evaluation gain: +261, Transferred to marketable securities: -3,496
Affiliates' stocks	50,351		49,910		-440	Toyama Chemical: -287, Yomeishu Seizo: -153
Deferred tax assets	10,729		9,916		-812	
Others	5,155		5,425		+270	
Total assets	618,434	100.0%	619,583	100.0%	+1,149	

(Liabilities)						
I Current liabilities:	59,859	9.7%	56,541	9.1%	-3,318	
Notes and accounts payable-trade	25,064		26,800		+1,736	Taisho: +2,081, Taisho Toyama: -456
Accounts payable	11,756		9,562		-2,193	Taisho: -1,706, Taisho Toyama: -180
Accrued corporate tax	8,019		2,697		-5,322	Decrease due to payment of taxes corresponding to tax return for fiscal year ended March 31, 2011
Allowance for bonuses	4,497		1,538		-2,959	Decrease due to reversal of summer bonuses
Provision for loss on disaster	1,044		255		-788	
Others	9,477		15,687		+6,209	Accrued expenses (summer bonuses and others): +5,983
II Long-term liabilities:	23,343	3.8%	23,345	3.8%	+1	
Reserves for retirement benefits	17,260		17,325		+65	
Deferred taxes liabilities	476		456		-20	
Others	5,606		5,563		-43	
Total liabilities	83,203	13.5%	79,887	12.9%	-3,316	
(Net assets)						
I Shareholders' equity	531,936	86.0%	535,785	86.5%	+3,848	
Common stock	29,804	4.8%	29,804	4.8%	-	
Additional paid-in capital	14,935	2.4%	14,935	2.4%	-	
Retained earnings	533,969	86.3%	537,881	86.8%	+3,912	Net income: +8,052, Payment of dividend: -4,140
Treasury stock	-46,772	-7.5%	-46,835	-7.5%	-63	
II Accumulated other comprehensive income	-7,434	-1.2%	-6,821	-1.1%	+612	
Unrealized gain on securities	1,939	0.3%	2,004	0.3%	+65	
Deferred gains or losses on hedges	-	-	-150	-0.0%	-150	
Foreign currency adjustment accounts	-9,373	-1.5%	-8,676	-1.4%	+697	
III Minority interest	10,728	1.7%	10,733	1.7%	+4	
Total net assets	535,231	86.5%	539,696	87.1%	+4,465	
Total liabilities and net assets	618,434	100.0%	619,583	100.0%	+1,149	

Consolidated P/L Statement

(Millions of yen)

	1Q FY2010		1Q FY2011		YOY Change	
		% Sales		% Sales		
Net sales	64,557	100.0%	64,265	100.0%	-291	Asia OTC: +267 Taisho Toyama: -635
Cost of sales	23,108	35.8%	23,157	36.0%	+49	
Gross profit on sales	41,448	64.2%	41,108	64.0%	-340	
Provision for sales returns	-35		-67		-32	
Gross profit	41,483	64.3%	41,175	64.1%	-308	
Selling, general and administrative expenses	29,560	45.8%	30,324	47.2%	+764	
Research and development expenses	4,743		4,996		+252	
Advertising expenses	3,414		3,463		+49	
Sales promotion expenses	5,126		5,745		+618	Expenses for a new product of prescription pharmaceutical and others
Personnel expenses	8,395		8,613		+218	
Others	7,880		7,505		-374	
Operating income	11,923	18.5%	10,851	16.9%	-1,072	
Non-operating income	2,019	3.1%	2,048	3.2%	+28	
Non-operating expenses	1,013	1.6%	340	0.5%	-672	Equity in losses of affiliates: -806
Ordinary income	12,930	20.0%	12,558	19.6%	-371	
Extraordinary gains	-	-	650	1.0%	+650	Reversal of provision for loss on disaster: +483
Extraordinary losses	13	0.0%	37	0.1%	+23	
Income before income taxes and minority interests	12,916	20.0%	13,171	20.5%	+255	
Income taxes	4,823	7.5%	4,938	7.7%	+114	
Income before minority interests	8,092	12.5%	8,233	12.8%	+140	
Minority interest gain of consolidated subsidiaries	383	0.6%	180	0.3%	-202	
Net income	7,708	11.9%	8,052	12.5%	+343	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2011(FY2010)				March 2012(FY2011)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Self-Medication operations* (YOY%)	39,920 (+3.5%)	85,424 (+4.6%)	131,133 (+5.2%)	167,195 (+5.3%)	39,853 (-0.2%)	87,000 (+1.8%)	171,300 (+2.5%)
Over-the-counter drugs, etc.	36,183	77,747	119,748	152,089	36,147	78,900	155,100
Foods for Specified Health Use and Foods, etc.	3,099	6,170	9,359	12,535	3,252	6,600	13,500
Others	638	1,507	2,026	2,571	454	1,500	2,700
Prescription Pharmaceutical operations (YOY%)	24,636 (-1.5%)	47,621 (-1.0%)	76,594 (-2.1%)	101,436 (+1.9%)	24,412 (-0.9%)	49,500 (+3.9%)	102,700 (+1.2%)
Ethical drugs	22,854	44,191	70,792	93,172	22,193	45,400	94,500
Intermediate products, etc.	1,759	3,340	5,690	7,919	2,174	4,000	7,900
Royalty income	23	90	112	345	45	100	300
Total	64,557	133,046	207,728	268,632	64,265	136,500	274,000

E=Estimates

Consolidated Operating Income by Segment

(Millions of yen)

	March 2011(FY2010)				March 2012(FY2011)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Self-Medication operations (YOY%)	9,378 (+43.9%)	20,933 (+30.0%)	32,472 (+30.7%)	38,385 (+26.0%)	9,384 (+0.1%)	20,400 (-2.5%)	36,400 (-5.2%)
Prescription Pharmaceutical operations (YOY%)	2,545 (-)	3,701 (+76.2%)	7,820 (+77.4%)	5,696 (+34.8%)	1,466 (-42.4%)	600 (-83.8%)	3,100 (-45.6%)
Total	11,923	24,635	40,292	44,082	10,851	21,000	39,500

E=Estimates

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of yen)

	March 2011(FY2010)				March 2012(FY2011)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
OTC drugs, etc.	36.2	77.7	119.7	152.1	36.1	-0.1%	78.9	155.1	+2.0%
Domestic OTC drugs	33.7	72.7	111.9	141.4	33.4	-1.1%	73.3	142.7	+0.9%
Lipovitan series	18.5	40.8	58.5	71.1	18.2	-1.7%	40.9	71.6	+0.7%
Pabron series	4.6	10.0	18.4	25.7	4.7	+2.3%	10.1	25.7	+0.1%
RiUP series	3.7	7.4	11.6	14.9	3.6	-2.8%	7.4	15.2	+2.4%
Naron series	1.1	2.2	3.7	4.6	0.9	-15.9%	2.2	4.3	-7.4%
Gastrointestinal treatment series	1.0	2.0	3.3	4.3	0.9	-1.5%	2.0	4.3	-0.7%
Colac Series	1.0	1.9	3.0	3.9	0.9	-1.8%	2.1	4.0	+4.4%
ZENA series	0.8	1.5	2.6	3.3	0.8	-4.6%	1.6	3.5	+3.6%
VICKS series	0.4	1.1	2.5	3.2	0.4	-7.1%	1.1	3.2	+0.9%
Biofermin Pharmaceutical	1.3	2.8	4.2	5.7	1.4	+6.1%	2.8	5.7	+0.2%
Asia OTC*	1.0	2.2	3.5	4.7	1.3	+25.8%	2.6	6.5	+40.3%
Foods for Specified Health Use and Foods, etc.	3.1	6.2	9.4	12.5	3.3	+4.9%	6.6	13.5	+7.7%
Livita series	0.9	1.7	2.6	3.6	1.0	+13.6%	1.8	3.7	+3.6%
Overseas energy drinks	1.6	3.3	4.8	6.3	1.6	-2.4%	3.2	6.5	+3.5%
Others	0.6	1.5	2.0	2.6	0.5	-28.8%	1.5	2.7	+5.0%

(Rounded to the nearest hundred-million)

E=Estimates

<Reference: Mail-order channel sales> FY2010: Yn 1.8 billion, 1Q/FY2011: Yn 0.5 billion

* The Asia OTC forecast for the fiscal year ending March 2012 includes projected net sales of Yn1.4 billion from Hoepharma Holdings Sdn. Bhd..

Lipovitan Series: Sales Breakdown

(Billions of yen)

	March 2011(FY2010)				March 2012(FY2011)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Lipovitan series	18.5	40.8	58.5	71.1	18.2	-1.7%	40.9	71.6	+0.7%
Lipovitan D	12.7	28.3	40.3	48.9	12.6	-0.9%	28.3	49.0	+0.2%
Others	5.7	12.5	18.2	22.2	5.5	-3.5%	12.6	22.6	+1.8%
(100mL other Lipovitans)	3.8	8.1	11.5	14.0	3.6	-5.1%	8.3	14.5	+3.6%
(50mL other Lipovitans)	1.9	4.4	6.7	8.2	1.9	-0.2%	4.3	8.1	-1.2%

(Rounded to the nearest hundred-million)

E=Estimates

Energy Drinks: Domestic Sales Breakdown by Channel

(Billions of yen)

	March 2011(FY2010)				March 2012(FY2011)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY
Drug-oriented channels	9.3	20.6	29.7	36.5	9.5	+2.1%
Food-oriented channels	10.3	22.6	32.8	39.6	10.0	-3.6%
Total	19.6	43.2	62.4	76.0	19.5	-0.9%

(Rounded to the nearest hundred-million)

Lipovitan D: Domestic Sales Breakdown by Channel

(Billions of yen)

	March 2011(FY2010)				March 2012(FY2011)	
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY
Drug-oriented channels	5.4	11.9	16.6	20.3	5.4	+0.9%
Food-oriented channels	7.4	16.4	23.7	28.6	7.2	-2.2%
Total	12.7	28.3	40.3	48.9	12.6	-0.9%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of yen)

	March 2011(FY2010)				March 2011(FY2010)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Clarith	5.4	9.6	16.6	22.9	4.8	-11.7%	9.4	22.0	-4.0%
ZOSYN	3.4	7.1	11.4	14.8	3.9	+14.5%	7.7	16.2	+9.8%
Palux	2.6	5.1	7.9	10.2	2.3	-10.2%	5.1	10.0	-2.2%
Geninax	1.0	2.3	3.2	4.5	0.8	-11.3%	2.3	5.0	+12.3%
OZEX	1.0	1.7	3.1	4.1	1.1	+11.1%	1.8	4.1	+0.0%
PENTCILLIN	1.0	2.0	3.0	3.8	0.8	-19.7%	1.8	3.4	-9.4%
Lorcam	0.9	1.8	2.8	3.6	0.9	-7.9%	1.7	3.3	-7.0%
TOMIRON	0.6	1.2	1.9	2.5	0.5	-15.1%	1.1	2.3	-6.7%
LUPRAC	0.6	1.1	1.7	2.2	0.6	-1.9%	1.1	2.2	-0.4%
Sumilu	0.5	1.0	1.5	1.9	0.5	-4.1%	1.1	2.0	+5.0%
Edirol	-	-	-	-	0.6	-	1.7	3.4	-

(Rounded to the nearest hundred-million)

E = Estimates

Major Subsidiaries: Trend of Sales and Earnings

Sales and Earnings of Taisho Toyama Pharmaceutical

(Billions of yen)

	March 2011(FY2010)				March 2011(FY2010)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	22.0	42.6	68.2	89.8	21.4	-2.9%	43.8	91.0	+1.4%
Taisho products	14.7	28.2	45.0	59.8	13.9	-5.7%	29.0	60.3	+0.9%
Toyama Chemical products	7.3	14.4	23.2	30.0	7.5	2.8%	14.8	30.7	+2.4%
Operating income	1.2	1.1	2.8	2.3	0.0	-96.4%	1.0	2.2	-4.9%
Ordinary income	1.2	1.1	2.8	2.3	0.1	-91.3%	1.1	2.3	-3.4%
Net income	0.6	0.4	1.3	0.9	-0.1	-	0.4	0.8	-2.7%

(Rounded to the nearest hundred-million)

E = Estimates

Sales and Earnings of Biofermin Pharmaceutical

(Billions of yen)

	March 2011(FY2010)				March 2011(FY2010)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	2.2	4.4	6.8	9.1	2.2	2.5%	4.5	9.1	+0.3%
Self-Medication	1.3	2.8	4.2	5.7	1.4	6.0%	2.8	5.7	+0.1%
Prescription Pharmaceutical	0.8	1.6	2.6	3.4	0.8	-3.1%	1.7	3.4	+0.7%
Operating income	0.7	1.3	2.0	2.4	0.7	-2.3%	1.3	2.3	-3.0%
Ordinary income	0.8	1.4	2.1	2.5	0.8	-2.6%	1.3	2.4	-3.7%
Net income	0.5	0.8	1.2	1.4	0.4	-2.6%	0.8	1.4	-0.8%

(Rounded to the nearest hundred-million)

E = Estimates

Consolidated: Capital Expenditure

(Millions of yen)

	March 2011(FY2010)				March 2012(FY2011)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total capital expenditure	701	1,944	2,990	7,870	771	3,400	11,000
Taisho Pharmaceutical	592	1,673	2,604	7,375	635	2,800	9,600
Omiya Factory	167	760	975	1,343	56	790	1,500
Hanyu Factory	19	31	31	107	-	-	30
Okayama Factory	22	46	53	170	17	20	50
Research Center	175	314	615	725	141	300	1,500
Others	209	522	928	5,029	420	1,690	6,520
Subsidiaries	109	270	385	494	136	600	1,400

E=Estimates

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2011(FY2010)				March 2012(FY2011)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Depreciation and amortization	2,850	5,742	8,696	11,725	2,694	5,400	11,100
Cost of sales	1,015	2,053	3,116	4,225	950	1,800	3,900
SGA expenses	1,835	3,688	5,580	7,499	1,743	3,600	7,200

E=Estimates

Consolidated: R&D Expenses

(Millions of yen)

	March 2011(FY2010)				March 2012(FY2011)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total R&D expenses	4,743	10,012	15,064	23,677	4,996	12,700	26,200
Self-Medication	1,101	2,341	3,438	4,677	1,194	2,800	6,100
Prescription Pharmaceutical	3,642	7,670	11,626	19,000	3,802	9,900	20,100

E=Estimates

Subsidiaries and Affiliates

(As of June 30, 2011)

Company	Address	Capital	Business	Ownership [*]
(1) Consolidated subsidiaries				%
Taisho Kosei Service Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000	SMG	100
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	56
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70
Medwell Taisho Co.,Ltd.	Saitama, Japan	,000 Yen 200,000	PD	100
Mejiro Real Estate Co.,Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100
Shimoda Central Co.,Ltd.	Tokyo, Japan	,000 Yen 300,000	SMG	100
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100
Taisho Pharmaceutical (M) SDN. BHD.	Malaysia	,000 M\$ 24,380	SMG	100
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100
PT. Taisho Indonesia	Indonesia	,000 rupiah 42,920,000	SMG	100
Taisho Foods Deutschland GmbH	Germany	,000 Euro 306	SMG	100
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100
Taisho Pharmaceutical Asia (M) SDN. BHD.	Malaysia	,000 M\$ 26,500	SMG	100
Taisho Pharmaceutical (Europe) Ltd.	United Kingdom	,000 £ 20,000	SMG	100
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100
Osotspa Taisho Co.,Ltd.	Thailand	,000 THB 15,000	SMG	49
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	99
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100
(2) Equity Accounting Method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000,000	PD	34
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	22
Taisho Hizon Manufacturing Inc.	Philippines	,000 Peso 17,000	SMG	50

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Prescription Pharmaceutical operations: New Drug Development

As of July 29, 2011

Development in Japan

Phase 2/3

1) CT-064 (Injection)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: RG484

Phase 2

1) TT-063

- < Application > Osteoarthritis, scapulohumeral periarthritis, myalgia and other conditions
- < Development > Co-development with Tokuhon
- < Description > Anti-inflammatory analgesic patch formulation containing S-flurbiprofen

2) TS-071

- < Application > Type 1 and 2 diabetes
- < Development > In-house
- < Description > Sodium-dependent glucose cotransporter (SGLT2) inhibitor

3) CT-064 (Oral)

- < Application > Osteoporosis
- < Development > Co-development with Chugai Pharmaceutical
- < Description > Antiresorptive bisphosphonate
- < Remarks > Chugai Pharmaceutical development code: RG484

4) NT-702

- < Application > Asthma
- < Development > Co-development with Nissan Chemical
- < Description > Expressed bronchodilatation and inhibition of cellular infiltration

5) NT-702

- < Application > Intermittent claudication caused by arteriosclerosis obliterans
- < Development > Co-development with Nissan Chemical
- < Description > Expressed vasodilation as well as platelet aggregate inhibition

6) Palux

- < Application > Intermittent claudication caused by spinal canal stenosis
- < Development > In-house
- < Description > Prostaglandin E1 preparation
- < Remarks > Additional indication

Launch of New Products

As of July 29, 2011

Self-Medication operations

1) ZENA F0-1α

< Description > A designated quasi drug mini-drink containing 7 types of nutrition-fortifying crude drugs
< Launch > October 2010

2) ZENA F0-Ginger

< Description > A designated quasi drug mini-drink containing 8 types of nutrition-fortifying crude drugs
< Launch > November 2010

3) Naturalcare Green Tea<GABA>

< Description > A green-tea PET bottle beverage, approved as a Foods for Specified Health Use (FOSHU), that is optimal for people with high blood pressure or blood-pressure concerns
< Launch > November 2010

4) Dermanin Grande Ice Spray

< Description > An ice spray-type athlete's foot treatment containing the antifungal agent terbinafine hydrochloride and anti-itch agents
< Launch > January 2011

5) Lipovitan D8

< Description > A designated quasi drug energy drink containing 10 ingredients, including royal jelly
< Launch > April 2011

6) Lipovitan Gold n

< Description > An energy mini-drink containing 3 types of nutrition-fortifying crude drugs and royal jelly, etc.
< Launch > April 2011

7) ALFE Fe up

< Description > An energy mini-drink containing the largest amount of iron in the ALFE series
< Launch > June 2011

Launch of New Products

As of July 29, 2011

Prescription Pharmaceutical operations
--

1) PASIL Injection 1000mg

< Description > New quinolone antibacterial product for injections
A new dosage formulation added to the existing PASIL injection 300mg/500mg
< Launch > October 2010

2) Ediol Capsules 0.5µg, 0.75µg

< Description > An active vitamin D3 derivative indicated for the effective treatment of osteoporosis
A drug that has an enhanced effect on bones
compared with existing active vitamin D3 derivatives
< Launch > April 2011
